BioMarin Pharmaceutical Inc. (BMRN) Price to Earnings Ratio

Corporate emblem and logo of BioMarin Pharmaceutical Inc. (BMRN)

BioMarin Pharmaceutical (BMRN) is minimizing risks by expanding access to rare disease therapies globally. The current P/E multiple on GURU.Markets reflects earnings dynamics, where -588.20 is the current value of the indicator. BioMarin Pharmaceutical (BMRN) controls drug synthesis while outsourcing logistics to partners. However, the slow rollout of gene products and the battle for the dwarfism market are putting pressure on financial results.

BioMarin Corp (BMRN) Price to Earnings Ratio: for the period 07/04/2022 - 11/14/2026

Comprehensive metric breakdowns and analytics for BioMarin Pharma (BMRN)

- price and consensus price forecast:
Stock Price biomarin.com|BMRN - Price Target Chart
- market capitalization details:
Market Value BioMarin Pharmaceutical|BMRN - Enterprise Value
- book capitalization information:
Net Assets per Share BioMarin|BMRN - Company Net Assets|Market Capitalization to Net Assets biomarin.com|BMRN - Company Total Assets
- debt and solvency information:
Debt to Capital BioMarin Pharmaceutical|BMRN - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio BioMarin Corp|BMRN - Company Total Debt|Debt to Net Assets Ratio BioMarin Pharmaceutical|BMRN - Company Long-Term Debt|Current Liabilities BioMarin|Intermediate Coverage Ratio biomarin.com
- earnings and market multiples details:
BMRN - Net Profit|Projected Future Earnings BioMarin Pharmaceutical|BMRN - Price to Earnings Ratio|Future Price to Earnings Multiple BioMarin Pharmaceutical Inc.|BMRN - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio BioMarin Pharmaceutical|BMRN - Operating profit EBITDA|Net earnings per share (EPS TTM) BioMarin|BMRN - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months biomarin.com|BMRN - Earnings growth in current year|Consensus forecast of earnings per share growth for next year BioMarin Pharmaceutical
- issuer revenue and sales details:
BMRN - Company Revenue|Company Expected Sales Volume biomarin.com|BMRN - Price-to-Revenue Ratio|Forward Price-to-Revenue Multiple BioMarin Pharmaceutical
General company analysis:biomarin.com - BMRN
Original product of biomarin.com

BioMarin Pharmaceutical (BMRN) is a recognized leader in developing life-saving therapies for orphan diseases. The P/E ratio measures the market value of a share relative to net income, reflecting the cost of one dollar of the company's earnings. By analyzing the P/E ratio trend, an investor compares current market capitalization with cash flows and dividend payments. A high multiple confirms market confidence in unique biotechnologies, although it requires validation through earnings growth rates.

Analysis of competing companies

P/E Multiple vrtx.com|Price to Earnings Ratio Alnylam (ALNY)|Price to Earnings Ratio INSM (Insmed Inc.)|P/E Multiple UTHR (United Therapeutics Corp.)|Business Payback Period BridgeBio Corp (BBIO)|BGM: Price to Earnings Ratio|Market Cap to Net Income COGT|XERS: P/E Multiple|Market Cap to Earnings Keros Therapeutics Inc (KROS)|ARCT (Arcturus Pharma) - P/E Multiple|Price to Earnings Multiple ETON (Eton Corp)|Price to Earnings Ratio KMDA (Kamada Ltd.)|FULC (fulcrumtx.com) - Company Value to Net Income|Price to Earnings Ratio Abeona Therapeutics Inc. ABEO|MREO (Mereo BioPharma Group) - Market Cap to Net Income|Protalix - P/E Multiple|Company Value to Net Income PLRX (Pliant Therapeutics)|APLT: P/E Multiple|aileronrx.com (RNTX) - P/E Multiple|Price to Earnings Ratio Gelteq Ltd|AYTU: Company Value to Net Income|Price to Earnings Ratio Chemomab Therapeutics (CMMB)|Price to Earnings Ratio srxhealth.com SRXH|P/E Multiple PLRZ (Polyrizon)|P/E Multiple Aeterna Zentaris Inc AEZS|Cyclo Therapeutics, Inc. - P/E Multiple|INZY: Price to Earnings Ratio|RPHM: P/E Multiple|CSCI - Business Payback Period